AR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Treatment with the AR antagonist enzalutamide was proven to be an effective therapeutic intervention for Xp11.2 tRCC by promoting the SUMOylation of TFE3 fusions.